# ‘No evidence’ of medicinal cannabis effectiveness treating anxiety, depression or PTSD > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-anxiety-depression-ptsd-evidence/ > **Published:** 2026-03-19T14:01:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:12-04:00 > **Clinical Summary:** Current cannabis anxiety depression PTSD evidence shows no support for medicinal cannabis effectiveness in treating these mental health conditions. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchMental HealthSafety Why This Matters Clinicians treating anxiety, depression, and PTSD should be aware that current evidence does not support cannabis as an effective treatment for these conditions, which may help prevent inappropriate recommendations to patients seeking alternatives. Patients considering cannabis for mental health conditions need accurate information about efficacy gaps to make informed decisions and pursue evidence-based treatments with established clinical benefits. This finding is particularly important given the increasing patient interest in cannabis as a psychiatric remedy and the potential delay in evidence-based care if clinicians default to cannabis recommendations. Clinical Summary A recent evidence review found insufficient clinical data to support [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) for anxiety, depression, or post-traumatic stress disorder, despite growing patient interest and off-label prescribing in these conditions. While cannabinoids have theoretical mechanisms that could affect mood and anxiety pathways, randomized controlled trials remain limited in number, quality, and sample size, preventing definitive conclusions about efficacy or optimal dosing. This evidence gap is particularly significant given that psychiatric conditions represent a substantial portion of cannabis use requests in clinical practice, yet clinicians lack robust data to guide treatment recommendations or predict individual patient responses. The lack of evidence does not necessarily mean cannabis is ineffective for these conditions, but rather highlights the need for rigorous clinical trials before it can be considered standard psychiatric care. Clinicians should be cautious about recommending [cannabis for anxiety](https://cedclinic.com/medical-cannabis-safety-facts/), depression, or PTSD until higher-quality evidence emerges, and should counsel patients that current research does not support these uses despite anecdotal reports of benefit. Until further research clarifies the role of cannabis in psychiatric care, clinicians should prioritize evidence-based treatments like cognitive behavioral therapy and FDA-approved medications while documenting patient requests for cannabis in these conditions to inform future research priorities. Dr. Caplan’s Take “After two decades of clinical experience, I can tell you that the absence of high-quality evidence for cannabis in anxiety, depression, and PTSD doesn’t match what I observe in my patients, but it also doesn’t give us license to prescribe it as a first-line treatment without honest conversation about that gap. What we’re really seeing is a research infrastructure failure, not a clinical failure, and patients deserve both rigorous trials and the acknowledgment that some find benefit while we figure out why.” Clinical Perspective While recent reviews highlighting insufficient evidence for cannabis in anxiety, depression, and PTSD align with regulatory caution, clinicians should recognize that absence of evidence in rigorous trials does not necessarily equate to absence of effect, particularly given historical research constraints and the heterogeneity of cannabis products, dosing regimens, and patient populations studied. The current evidence gap reflects genuine methodological challenges—including difficulty conducting placebo-controlled trials, variability in cannabinoid ratios, and limited long-term safety data—rather than definitive proof of inefficacy. Notably, many patients report subjective symptom relief, and some observational data suggest potential benefit for specific presentations, creating a tension between individual patient experience and population-level evidence standards. Until higher-quality trials clarify efficacy and establish optimal dosing, clinicians should discuss both the limited empirical support and the uncertainty surrounding cannabis use with patients seeking it for mood or trauma-related disorders 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+%27No+evidence%27+of+medicinal+cannabis+effectiveness+treating+anxiety%2C+depression+or+PTSD+%40drcaplan&url=https%3A%2F%2Fwww.hospitalhealth.com.au%2Fcontent%2Fclinical-services%2Farticle%2F-no-evidence-of-medicinal-cannabis-effectiveness-treating-anxiety-depression-or-ptsd-692927660)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.hospitalhealth.com.au%2Fcontent%2Fclinical-services%2Farticle%2F-no-evidence-of-medicinal-cannabis-effectiveness-treating-anxiety-depression-or-ptsd-692927660)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+%27No+evidence%27+of+medicinal+cannabis+effectiveness+treating+anxiety%2C+depression+or+PTSD+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.hospitalhealth.com.au%2Fcontent%2Fclinical-services%2Farticle%2F-no-evidence-of-medicinal-cannabis-effectiveness-treating-anxiety-depression-or-ptsd-692927660)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [PM News Update: March 17, 2026](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/) - [PM News Update: March 17, 2026](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/) 📰 Source: [https://www.hospitalhealth.com.au/content/clinical-services/article/-no-evidence-of-medicinal-cannabis-effectiveness-treating-anxiety-depression-or-ptsd-692927660](https://www.hospitalhealth.com.au/content/clinical-services/article/-no-evidence-of-medicinal-cannabis-effectiveness-treating-anxiety-depression-or-ptsd-692927660) Further Reading Evidence Watch[Cannabinoid Clinical Trials: CBD & Cortical Excitability](https://cedclinic.com/cbd-anti-seizure-properties-cortical-excitability-trial/) Cannabis Policy Wire[Policy Watch: 5 Regulatory Updates — March 19, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-2026-regulatory-updates/) CED Clinic Blog[A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.](https://cedclinic.com/cannabidiol-effects-on-appetite/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Largest-Ever Study Finds Medicinal Cannabis Ineffective for Anxiety, Depression, PTSD](https://cedclinic.com/medicinal-cannabis-mental-health-efficacy-study-review/) Explore the comprehensive study revealing the lack of medicinal cannabis effectiveness for anxiety, depression, and PTSD. [Read the full study](https://cedclinic.com/medicinal-cannabis-mental-health-efficacy-study-review/) [Scientists find no convincing evidence of cannabis effectiveness for mental health: review](https://cedclinic.com/cannabis-mental-health-treatment-challenges-evidence-review/) A detailed review summarizing the scientific consensus on [cannabis and mental health](https://cedclinic.com/endocannabinoid-system-fear-extinction/) treatment efficacy. [Learn more](https://cedclinic.com/cannabis-mental-health-treatment-challenges-evidence-review/) [Cannabinoid Clinical Trials: Mental Health Evidence Review](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Review of clinical trials assessing cannabinoids for mental health conditions including anxiety and depression. [Explore clinical trials](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).